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照处理下有协同效应对细胞毒性更强；添加不同的 ROS 抑制剂，用 MTT 法比较
细胞活性的改变，L-组氨酸和 NAC（两种单线态氧清除剂）的添加显著提高了















积累量，再进一步由 ABDA 检测单线态氧产率；用钙黄绿素/PI 双染法做活细胞
/死细胞双重染色，观察细胞死亡情形；通过 Fura-2/AM 探针检测细胞内 Ca2+浓
度。结果显示富勒烯-环糊精/沙利度胺包合物光照处理下会发生光动力作用，使






















Currently tumor incidence is rising year by year. Since traditional therapies have 
some disadvantages, such as high risk and side effects, people are seeking for safer 
and more effective treatment. Photodynamic therapy is non-invasive and can be 
repeated multiple times safely. Antiangiogenic therapy targets the tumor vascular 
endothelial cells, which means low systematic toxicity and not prone to be 
drug-resistant. Its cooperative use with antitumor can display significant synergistic 
effect. Nanoparticle delivery system based on the EPR effect or modified with 
targeting groups can be passively or actively targeting to the tumor tissue, which may 
show excellent antitumor effect. 
Our work aims to synthesize an inclusion compound, fullerene- 
cyclodextrin/thalidomide. β-cyclodextrin can enhance the biocompatibility of the 
system and the drug can be included into its cage, fullerene can generate ROS to kill 
the tumor cells (tumor parenchyma), and thalidomide can kill tumor vascular 
endothelial cells (tumor stroma). In this way it plays a synergistic effect.The potential 
superiority of this nano-drug carrier is good biocompatibility, good drug solubility 
with high drug loading ratio and passively targeting to malignant cells. 
Our paper covers the research process of the inclusion compound, including the 
ideas, methods, characterization and its applications. The methods and results are 
listed below: In Chapter 2, we obtained the fullerene amino derivatives (C60-NH2) 
from the addition reaction between ethylenediamine and the carboxyl cyclodextrin 
derivatives (MAH-β-CD) from the reaction between maleic anhydride and beta 
cyclodextrin. These two products were coupled through amidation reaction. Finally 
the drug thalidomide was included into the cage of beta cyclodextrin. We analysed the 
structure by FT-IR, MS, UV-Vis, NMR etc. It was confirmed that 
cyclodextrin-fullerene conjugate is with molar ratio 1:1. Then thalidomide was 
included and the drug loading ratio was 7.34％. It had drug sustained release. In 
Chapter 3, HeLa cells were co-cultured with inclusion compound of different 















which indicated that the carrier had no dark cytotoxicity and was biocompatible. After 
illumination, it had cytotoxicity because of the photodynamic effect. The inclusion 
compound had drug sustained-releas in dark, which lead to cytotoxicity. And it had 
more cytotoxicity with illumination. After cells added with different ROS scavengers 
we measured it again by MTT assay. L-histidine and NAC (two kinds of singlet 
oxygen scavengers) improved cell viability more significantly, so we make sure that 
the photodynamic reaction is mostly based on Type II mechanism. Relative 
accumulation of intracellular ROS was measured by flow cytometry and 1O2 yield 
was measured with ABDA. We observed the cell death by calcein-AM/PI double 
staining. The intracellular free calcium concentration was analyzed by the fluorescent 
calcium indicator Fura-2/AM. The results showed that cyclodextrin- 
fullerene/thalidomide inclusion compound had photodynamic reaction, which lead to 
cell damage, the elevation of intracellular ROS and Ca2+. In Chapter 4, We analysized 
the inhibition of inclusion compound on HUVEC cell proliferation, migration and 
tube formation by MTT assay, cell scratch wound assay, Transwell invasion 
experiment and the tube formation assay. It showed that the inclusion compound 
significantly inhibited in-vitro angiogenesis because of synergistic effect. In summary, 
we synthesized a new kind of inclusion compound, 
cyclodextrin-fullerene/thalidomide, which has photodynamic effect and 
anitiangiogenic effect. It produced effects on tumor parenchyma and stroma at the 
same time. 
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1985 年，Kroto 等[7]通过控制反应条件同时得到了 C60 和 C70 两种物质。富






































图 1-1 光动力反应过程 





















derivative， HpD）为代表，其应用与研究也最详细，后来又从 HpD 中分离纯化
出光敏素 2（photofrin 2），而中国成功研制了癌光啉、癌光啉、光卟啉三种混合
卟啉制剂，并成功用于国内的临床治疗[17]。第二代光敏剂大多是单体化合物（包






























图 1-2 富勒烯 C60 的化学结构 
Figure 1-2 Chemical structure of fullerene C60 
富勒烯 C60 的主要物理性质如表 1-1 所示[19]。 
表 1-1 C60 的主要物理性质 
Table 1-1 The main physical properties of C60 
性质 C60 
分子结构 凸三十二面体 
分子大小 直径约 7.1 Å 
































鼠细胞系（J774、LLC 和 CT26）共培育 24 h 后，用白光（400–700 nm，150 mW/cm2）
照射后具有显著的光动力效果，发现单阳离子修饰的富勒烯衍生物具有很高的光
动力活性，由活性氧簇（ROS）探针检测出其光动力机制主要是 Type I 机制（能
量转移途径）。Li 等[24]发现富勒烯氨基酸衍生物与人肝癌细胞共培育后，经白炽
灯（75 W）光照（0-60 min）后癌细胞大量死亡。 
富勒烯 C60 是一种闭环纳米碳材料，由于富勒烯 C60扩展的 π 键共轭，它可
以吸收紫外光和可见光，具有很高的三重态产率，是已报道的光敏剂中单线态氧
产率最高的，高达 95%，因此它在光动力治疗方面具有很高的应用可能。
Yamakoshi 等[25]研究富勒烯的光动力机制时，发现 C60 在非极性溶剂中受激发主
要生成超氧阴离子自由基 O2-·和羟自由基·OH，而在极性溶剂中更易生成 1O2，
特别是在 NADH（一种还原性还原型辅酶 I）存在的情况下。Miyata 等[26]合成一
种水溶性富勒烯/聚乙烯吡咯烷酮（C60/PVP）体系，利用电子顺磁共振（electron 
paramagnetic resonance，EPR）自旋捕获方法仅检测到 O2-·和·OH 的生成，这
表明 C60−•与分子氧之间发生电子转移反应。Yu 等[27]合成的六磺丁基富勒烯
（FC4S）相比于 C60/γ-环糊精的包合物体系单线态产率为 0.36，说明了其中的机
制是 Type I 能量转移。 
C60 生成 ROS 的过程如图 1-3 所示[25]。 
 
图 1-3 C60 生成 ROS 过程 
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